#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	3350	16S	1529	1529	100.0	16S.l15.c30.ctg.1	2471	399.8	1	SNP	n	C1184T	0	.	.	1184	1184	C	1628	1628	C	458	C	412	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5330	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4079	390.9	0	.	n	.	0	T695C	SNP	695	695	T	1368	1368	C	378	C,T	335,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5330	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4079	390.9	0	.	n	.	0	G1337A	SNP	1337	1337	G	2010	2010	A	469	A,G	425,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5330	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4079	390.9	0	.	n	.	0	T1971C	SNP	1971	1971	T	2644	2644	C	509	C,T,A	448,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5330	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4079	390.9	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	3270	3270	T	493	T	443	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5330	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4079	390.9	1	SNP	n	A2045G	0	.	.	2045	2045	A	2718	2718	A	525	A	482	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	564	folP	852	852	100.0	folP.l15.c4.ctg.1	1980	84.9	1	SNP	p	R228S	1	.	.	682	684	AGC	1251	1253	AGC	124;124;124	A;G;C	109;112;112	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1182	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	4153	85.3	1	SNP	p	S91F	0	.	.	271	273	TCC	913	915	TCC	119;117;116	T;C;C	101;104;104	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1182	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	4153	85.3	1	SNP	p	D95G	0	.	.	283	285	GAC	925	927	GAC	114;114;113	G;A;C	106;102;102	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1182	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	4153	85.3	1	SNP	p	D95N	0	.	.	283	285	GAC	925	927	GAC	114;114;113	G;A;C	106;102;102	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_W_01449	mtrR.WHO_W_01449	1	1	27	506	mtrR	633	633	99.84	mtrR.l6.c4.ctg.1	1822	82.9	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	300	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1516	59.2	0	.	n	.	0	C187G	SNP	187	187	C	803	803	G	108	G	98	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1208	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3622	100.0	1	SNP	p	D86N	0	.	.	256	258	GAC	877	879	GAC	134;134;134	G;A;C	117;108;117	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1208	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3622	100.0	1	SNP	p	S87I	0	.	.	259	261	AGT	880	882	AGT	135;135;135	A;G,T;T,C	113;116,1;112,1	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1208	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3622	100.0	1	SNP	p	S87R	0	.	.	259	261	AGT	880	882	AGT	135;135;135	A;G,T;T,C	113;116,1;112,1	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1208	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3622	100.0	1	SNP	p	S87W	0	.	.	259	261	AGT	880	882	AGT	135;135;135	A;G,T;T,C	113;116,1;112,1	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1208	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3622	100.0	1	SNP	p	S88P	0	.	.	262	264	TCC	883	885	TCC	135;132;132	T;C;C	111;115;107	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	990	parE	1986	1986	100.0	parE.l6.c4.ctg.1	3033	97.4	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1771	1773	GGC	102;102;102	G;G;C	95;88;88	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	840	penA	1749	1749	100.0	penA.l6.c17.ctg.1	3153	79.4	1	SNP	p	A311V	0	.	.	931	933	GCA	1680	1682	GCA	143;143;141	G;C;A	134;127;133	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	840	penA	1749	1749	100.0	penA.l6.c17.ctg.1	3153	79.4	1	SNP	p	I312M	0	.	.	934	936	ATC	1683	1685	ATC	141;140;141	A;T;C	133;129;126	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	840	penA	1749	1749	100.0	penA.l6.c17.ctg.1	3153	79.4	1	SNP	p	V316P	0	.	.	946	948	GTG	1695	1697	GTG	150;150;154	G;T,G;G,T	138;139,1;138,1	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	840	penA	1749	1749	100.0	penA.l6.c17.ctg.1	3153	79.4	1	SNP	p	V316T	0	.	.	946	948	GTG	1695	1697	GTG	150;150;154	G;T,G;G,T	138;139,1;138,1	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	840	penA	1749	1749	100.0	penA.l6.c17.ctg.1	3153	79.4	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2199	2201	ACC	97;96;97	A,C;C;C	83,1;81;88	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	840	penA	1749	1749	100.0	penA.l6.c17.ctg.1	3153	79.4	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2253	2255	GCG	90;89;89	G;C,G;G,C	77;68,1;68,1	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	840	penA	1749	1749	100.0	penA.l6.c17.ctg.1	3153	79.4	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2253	2255	GCG	90;89;89	G;C,G;G,C	77;68,1;68,1	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	840	penA	1749	1749	100.0	penA.l6.c17.ctg.1	3153	79.4	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2376	2378	GGC	99;98;98	G,C;G,T;C	87,1;86,1;86	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	840	penA	1749	1749	100.0	penA.l6.c17.ctg.1	3153	79.4	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2385	2387	GGC	100;99;99	G;G;C	84;85;86	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	840	penA	1749	1749	100.0	penA.l6.c17.ctg.1	3153	79.4	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2403	2405	CCG	95;96;97	C;C;G	81;82;82	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	27	1180	ponA	2397	2397	99.96	ponA.l15.c30.ctg.1	3501	100.8	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1800	1802	CTG	105;105;106	C,G;T,G;G	93,1;87,1;94	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	674	porA	1146	1146	99.83	porA.l6.c4.ctg.1	2301	87.9	0	.	p	.	0	M83fs	FSHIFT	247	247	A	861	861	C	99	C	88	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	76	porB1a	984	184	90.96	porB1a.l15.c4.ctg.1	1462	15.5	0	.	p	.	0	H217N	NONSYN	649	651	CAT	1303	1305	AAT	10;10;10	A;A;T	10;10;10	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	76	porB1a	984	184	90.96	porB1a.l15.c4.ctg.1	1462	15.5	0	.	p	.	0	D218N	NONSYN	652	654	GAT	1306	1308	AAT	9;9;9	A;A;T	8;8;7	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	76	porB1a	984	184	90.96	porB1a.l15.c4.ctg.1	1462	15.5	0	.	p	.	0	A222V	NONSYN	664	666	GCT	1318	1320	GTT	8;8;8	G;T;T	8;8;7	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	76	porB1a	984	184	90.96	porB1a.l15.c4.ctg.1	1462	15.5	0	.	p	.	0	V226A	NONSYN	676	678	GTA	1330	1332	GCA	7;7;7	G;C;A	7;7;7	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	76	porB1a	984	184	90.96	porB1a.l15.c4.ctg.1	1462	15.5	0	.	p	.	0	.	MULTIPLE	700	702	ACT	1353	1355	GTA	7;7;7	G;T;A	7;6;7	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	76	porB1a	984	184	90.96	porB1a.l15.c4.ctg.1	1462	15.5	0	.	p	.	0	N237fs	FSHIFT	709	709	A	1362	1362	A	6	A	6	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	678	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1557	121.8	0	.	p	.	0	G38E	NONSYN	112	114	GGA	369	371	GAA	131;131;133	G;A;A	113;117;120	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	678	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1557	121.8	0	.	p	.	0	S46G	NONSYN	136	138	AGC	393	395	GGC	132;132;132	G,T;G;C,A	117,1;116;115,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	678	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1557	121.8	0	.	p	.	0	E48G	NONSYN	142	144	GAA	399	401	GGA	132;132;132	G;G;A	113;114;115	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	678	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1557	121.8	0	.	p	.	0	T87A	NONSYN	259	261	ACT	516	518	GCT	139;138;138	G;C;T	123;119;122	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	678	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1557	121.8	0	.	p	.	0	T89S	NONSYN	265	267	ACC	522	524	AGC	135;135;136	A,C;G;C,T	120,1;121;120,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	678	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1557	121.8	0	.	p	.	0	.	MULTIPLE	358	359	AA	614	615	CG	131;130	C;G	126;121	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	678	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1557	121.8	0	.	p	.	0	.	MULTIPLE	361	362	GA	617	619	CAG	131;131;129	C;A;G	122;126;121	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	678	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1557	121.8	0	.	p	.	0	N122K	NONSYN	364	366	AAC	621	623	AAA	131;131;131	A;A;A	125;123;124	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	678	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1557	121.8	0	.	p	.	0	K143E	NONSYN	427	429	AAA	684	686	GAA	134;135;135	G;A;A	122;124;119	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	678	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1557	121.8	0	.	p	.	0	V151A	NONSYN	451	453	GTA	708	710	GCA	133;133;133	G;C;A	118;116;119	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	678	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1557	121.8	0	.	p	.	0	Q187R	NONSYN	559	561	CAA	816	818	CGA	126;126;126	C;G;A	112;113;112	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	678	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1557	121.8	0	.	p	.	0	A215T	NONSYN	643	645	GCT	900	902	ACT	137;137;136	A;C;T	118;118;117	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	678	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1557	121.8	0	.	p	.	0	Y216H	NONSYN	646	648	TAT	903	905	CAT	136;136;136	C;A;T,C	117;121;119,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	678	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1557	121.8	0	.	p	.	0	I218M	NONSYN	652	654	ATA	909	911	ATG	134;134;133	A;T;G	121;119;117	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	678	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1557	121.8	0	.	p	.	0	.	MULTIPLE	766	767	AC	1023	1025	GCA	128;127;127	G;C;A,C	120;116;119,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	678	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1557	121.8	0	.	p	.	0	W257R	NONSYN	769	771	TGG	1027	1029	CGG	126;126;126	C,A;G;G	117,1;113;119	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	678	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1557	121.8	0	.	p	.	0	S258fs	FSHIFT	772	772	A	1030	1030	A	125	A	115	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	678	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1557	121.8	1	SNP	p	G120K	1	.	.	358	360	AAG	614	616	CGG	131;130;130	C;G;G,C	126;121;122,1	porB1b.WHO_L_01891c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	678	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1557	121.8	1	SNP	p	D121N	0	.	.	361	363	GAC	617	620	CGC	131;129;130	C;G;C	122;121;123	porB1b.WHO_L_01891c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	678	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1557	121.8	1	SNP	p	A121D	1	.	.	361	363	GAC	617	620	CGC	131;129;130	C;G;C	122;121;123	porB1b.WHO_L_01891c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	2162	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	5570	116.4	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2388	2390	AAT	149;150;150	A;A,G;T	137;138,1;135	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	316	rpsJ	312	312	100.0	rpsJ.l6.c4.ctg.1	1484	63.7	1	SNP	p	V57M	1	.	.	169	171	ATG	694	696	ATG	119;119;120	A;T;G	106;109;110	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
